• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Show Search
Home
EN / FR
  • LinkedIn
  • Twitter
Celyad Oncology

Celyad Oncology

  • About Us
    • Overview
    • Management Team
    • Board Of Directors
    • Scientific Advisory Board
    • Partners
  • Science
    • Overview
    • Approach
    • Technology
      • TIM
      • shRNA
    • Manufacturing
    • Scientific Publications
  • Pipeline
  • Newsroom
    • Press Releases
    • Events
    • Media Center
  • Investors
    • Overview
    • Analyst Coverage
    • Corporate Governance
    • Regulated Information
    • Shareholders Information
    • Shareholders Meeting
  • Contact Us
    • Careers

Cardio3 BioSciences Announces Completion of its Capital Increase of €25 Million at €44 per share.

July 1, 2014 By Celyad

  • This capital increase completes the first part of the agreement with Medisun International Limited
  • Total deal with Medisun valued at €70 million.

Mont-Saint-Guibert, Belgium, – Cardio3 BioSciences (C3BS) (Euronext Brussels and Paris: CARD), a leader in the discovery and development of advanced regenerative therapies for heart disease, today announces the completion of a capital increase of €25 million at €44 a share initiated on 16 June 2014. The capital increase was fully subscribed on 16 June 2014 and occurred in two tranches of €12.5 million each. All new shares are subscribed for by Medisun International Limited, a investment holding company based in Hong Kong.

As a result of this first investment, Medisun owns approximately 8% of the Company’s outstanding shares. The proceeds of this capital increase will provide Cardio3 BioSciences with the financial means to start the U.S. Food and Drug Administration (FDA) approved CHART-2 trial for C-Cure®. In addition, the funds will support the Company’s pipeline development and other general corporate purposes. 

The agreement with Medisun also comprises the incorporation of the Joint Venture with the purpose to conduct pivotal clinical trials in Greater China, ie the People’s Republic of China, Hong Kong and Taiwan. To the exception of the production of the cells, all the operational costs of the Joint Venture will be financed by Medisun, with a minimum committed of €20 million over a three year period.

Finally, Medisun has also committed over the next eight months to purchase additional shares of Cardio3 BioSciences from existing shareholders for up to €25 million at a price per share equivalent to the 10 days average preceding the offer(s).

Download press release(s)
Communiqué de presse
Press Release

Filed Under: Corporate, Regulated

Footer

  • About
  • Science
  • Pipeline
  • Newsroom
  • Investors
  • Contact Us
  • LinkedIn
  • Twitter

Copyright © 2020 All Rights Reserved.
Cookie Policy | Privacy Policy | Terms of Use

Our website uses cookies including analytics cookies to help improve it by collecting statistics on how visitors use our website. By clicking on "I accept", you allow us to place these analytics cookies. We also use cookies that are necessary for the good functioning of our website. You can find out more information about the cookies we use by visiting our Cookie Policy. I acceptI refuseCookie Policy